Abstract
The HOXB13 gene is a member of the homeobox gene family, and prostate development depends on HOXB13 function. HOXB13 is a very sensitive and specific marker of prostate tissue and prostate cancer. When the origin of a tumor in a resection specimen or in biopsy material is unclear, it allows determining the prostate as the primary. Our aim was to determine whether HOXB13 has similar sensitivity for determining prostate origin of lymph node and bone metastases. We retrieved cases of lymph node and bone metastases of histologically confirmed prostate cancer (PCa) and selected lymph node metastases of urothelial carcinoma (UCa). A panel of antibodies against HOXB13, PSA, ERG, Androgen receptors, p504S, p63, GATA-3, CK7, and Uroplakin 2 and 3 was tested on these tissue samples. Two pathologists analysed and scored staining as either 0 (negative) or + (positive). The selected cohort consisted of 74 cases of lymph node and 15 of bone metastases of PCa and 15 of lymph node metastases of UCa. HOXB13 was expressed in 93 % of lymph node and in 33 % of bone metastases of PCa. All lymph node metastases of UCa were negative. Sensitivity of HOXB13 as a marker for prostate origin in lymph node metastases was 93 % and for bone metastases 33 %. Inter-observer variability in assessment of staining was good, as only two (1.9 %) of lymph node metastasis of PCa were discordant. HOXB13 is a useful marker for prostate origin when doubt exists regarding the site of the primary of a metastatic lesion. On bone metastases, HOXB13 immunohistochemistry performed less well, probably due to the use of tissue decalcification.
Similar content being viewed by others
References
Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. (2012) Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med 366:141–149
Varinot J, Cussenot O, Roupret M, Conort P, Bitker M-O, Chartier-Kastler E, et al. (2013) HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch 463:803–809
MB A, Trpkov K, Lopez-Beltran A, Grignon D, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e20–e34
Smith SC, Palanisamy N, Zuhlke KA, Johnson AM, Siddiqui J, Chinnaiyan AM, HOXB13, et al. (2014) G84E-related familial prostate cancers: a clinical, histologic, and molecular survey. Am J Surg Pathol 38:615–626
Jourdan F, Sebbagh N, Comperat E, Mourra N, Flahault A, Olschwang S, et al. (2003) Tissue microarray technology: validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch 443:115–121
Parwani AV, Herawi M, Epstein JI (2006) Pleomorphic giant cell adenocarcinoma of the prostate: report of 6 cases. Am J Surg Pathol 30:1254–1259
Gurel B, Ali TZ, Montgomery EA, Begum S, Hicks J, Goggins M, et al. (2010) NKX3.1 as a marker of prostatic origin in metastatic tumors. Am J Surg Pathol 34:1097–1105
Ud Din N, Qureshi A, Mansoor S (2011) Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. Indian J Pathol Microbiol 54:59–62
Jiang Z, Woda BA, Rock KL, Xu Y, Savas L, Khan A, et al. (2001) P504S: a new molecular marker for the detection of prostate carcinoma. Am J Surg Pathol 25:1397–1404
Luo J, Zha S, Gage WR, Dunn TA, Hicks JL, Bennett CJ, et al. (2002) Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer. Cancer Res 62:2220–2226
Chuang A-Y, DeMarzo AM, Veltri RW, Sharma RB, Bieberich CJ, Epstein JI (2007) Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma. Am J Surg Pathol 31:1246–1255
JI E, Egevad L, PA H, Montironi R, Members of the ISUP Immunohistochemistry in Diagnostic Urologic Pathology Group (2014) Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference. Am J Surg Pathol 38:e6–19
Acknowledgments
The authors thank Annette Lesot for the technical assistance.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Varinot, J., Furudoï, A., Drouin, S. et al. HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin. Virchows Arch 468, 619–622 (2016). https://doi.org/10.1007/s00428-016-1917-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00428-016-1917-x